Stemline Therapeutics announces positive clinical data from ELZONRISTM trials
Stemline Therapeutics announced positive clinical data from ELZONRISTM (tagraxofusp; SL-401) trials. ELZONRIS demonstrated high response rates and high rate of stem cell transplant in blastic plasmacytoid dendritic cell neoplasm. June 18, 2018